Moxibustion treatment modulates the gut microbiota and immune function in a dextran sulphate sodium-induced colitis rat model

Qin Qi, Ya Nan Liu, Xiaoming Jin, Lin Shuang Zhang, Cun Wang, Chun Hui Bao, Hui Rong Liu, Huan Gan Wu, Xiao Mei Wang

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

AIM To investigate the effect and mechanism of moxibustion in rats with ulcerative colitis. METHODS A rat colitis model was established by administering 4% dextran sulphate sodium solution. Seventy male rats were randomly divided into seven groups: Healthy controls (HC), ulcerative colitis model group (UC), UC with 7 d of moxibustion (UC-7), UC with 14 d of moxibustion (UC-14), UC with mesalazine gavage (UC-W), HC with 7 d of moxibustion (HC-7), HC with 14 d of moxibustion (HC-14). Moxibustion was applied to the bilateral Tianshu (ST25). Gut microbiome profiling was conducted by 16S rRNA amplicon sequencing, and PCR and ELISA determined the expression of inflammatory cytokines in colon mucosa and serum, respectively. RESULTS Moxibustion treatment restored the colonic mucosa and decreased submucosal inflammatory cell infiltration in colitis rats. Rats treated with moxibustion and mesalazine had significantly lower levels of the dominant phyla Proteobacteria and the genera Saccharibacteria , Sphingomonas and Barnesiella than colitis rats, and they could restore the microbiome to levels similar to those observed in healthy rats. UC rats had reduced alpha diversity, which could be alleviated by moxibustion therapy, and UC-7 had a higher alpha diversity than UC-14. This finding suggests that short-term (7 d) but no longer term (14 d) moxibustion treatment may significantly affect the gut microbiome. The potential bacterial functions affected by moxibustion may be ascorbate and aldarate metabolism, and amino acid metabolism. Compared with HC group, the levels of the cytokines interleukin-12 (IL-12) (P < 0.05) and IL-6, IL-17, IL-23, interferon-?, lipopolysaccharide, IgA, tumour necrosis factor-a and its receptors 1 (TNFR1) and TNFR2 (P < 0.01) were all increased, whereas anti-inflammatory cytokine IL-2 and IL-10 (P < 0.01) and transforming growth factor-β (P < 0.05) were decreased in UC rats. These changes were reversed by moxibustion. Our findings suggest that moxibustion exerts its therapeutic effect by repairing mucosal tissue damage and modulating the gut microbiome and intestinal mucosal immunity.

Original languageEnglish (US)
Pages (from-to)3130-3144
Number of pages15
JournalWorld Journal of Gastroenterology
Volume24
Issue number28
DOIs
StatePublished - Jul 28 2018
Externally publishedYes

Fingerprint

Moxibustion
Dextran Sulfate
Colitis
Therapeutics
Mesalamine
Mucous Membrane
Cytokines
Ulcerative Colitis
Gastrointestinal Microbiome
Sphingomonas
Receptors, Tumor Necrosis Factor, Type II
Interleukin-23
Proteobacteria
Mucosal Immunity
Control Groups
Interleukin-17
Microbiota
Transforming Growth Factors
Therapeutic Uses
Interleukin-12

Keywords

  • 16S rRNA
  • Gut microbiome
  • Inflammatory cytokine
  • Moxibustion
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Moxibustion treatment modulates the gut microbiota and immune function in a dextran sulphate sodium-induced colitis rat model. / Qi, Qin; Liu, Ya Nan; Jin, Xiaoming; Zhang, Lin Shuang; Wang, Cun; Bao, Chun Hui; Liu, Hui Rong; Wu, Huan Gan; Wang, Xiao Mei.

In: World Journal of Gastroenterology, Vol. 24, No. 28, 28.07.2018, p. 3130-3144.

Research output: Contribution to journalArticle

Qi, Qin ; Liu, Ya Nan ; Jin, Xiaoming ; Zhang, Lin Shuang ; Wang, Cun ; Bao, Chun Hui ; Liu, Hui Rong ; Wu, Huan Gan ; Wang, Xiao Mei. / Moxibustion treatment modulates the gut microbiota and immune function in a dextran sulphate sodium-induced colitis rat model. In: World Journal of Gastroenterology. 2018 ; Vol. 24, No. 28. pp. 3130-3144.
@article{a827534fd69f4f9599782ca4acedbfca,
title = "Moxibustion treatment modulates the gut microbiota and immune function in a dextran sulphate sodium-induced colitis rat model",
abstract = "AIM To investigate the effect and mechanism of moxibustion in rats with ulcerative colitis. METHODS A rat colitis model was established by administering 4{\%} dextran sulphate sodium solution. Seventy male rats were randomly divided into seven groups: Healthy controls (HC), ulcerative colitis model group (UC), UC with 7 d of moxibustion (UC-7), UC with 14 d of moxibustion (UC-14), UC with mesalazine gavage (UC-W), HC with 7 d of moxibustion (HC-7), HC with 14 d of moxibustion (HC-14). Moxibustion was applied to the bilateral Tianshu (ST25). Gut microbiome profiling was conducted by 16S rRNA amplicon sequencing, and PCR and ELISA determined the expression of inflammatory cytokines in colon mucosa and serum, respectively. RESULTS Moxibustion treatment restored the colonic mucosa and decreased submucosal inflammatory cell infiltration in colitis rats. Rats treated with moxibustion and mesalazine had significantly lower levels of the dominant phyla Proteobacteria and the genera Saccharibacteria , Sphingomonas and Barnesiella than colitis rats, and they could restore the microbiome to levels similar to those observed in healthy rats. UC rats had reduced alpha diversity, which could be alleviated by moxibustion therapy, and UC-7 had a higher alpha diversity than UC-14. This finding suggests that short-term (7 d) but no longer term (14 d) moxibustion treatment may significantly affect the gut microbiome. The potential bacterial functions affected by moxibustion may be ascorbate and aldarate metabolism, and amino acid metabolism. Compared with HC group, the levels of the cytokines interleukin-12 (IL-12) (P < 0.05) and IL-6, IL-17, IL-23, interferon-?, lipopolysaccharide, IgA, tumour necrosis factor-a and its receptors 1 (TNFR1) and TNFR2 (P < 0.01) were all increased, whereas anti-inflammatory cytokine IL-2 and IL-10 (P < 0.01) and transforming growth factor-β (P < 0.05) were decreased in UC rats. These changes were reversed by moxibustion. Our findings suggest that moxibustion exerts its therapeutic effect by repairing mucosal tissue damage and modulating the gut microbiome and intestinal mucosal immunity.",
keywords = "16S rRNA, Gut microbiome, Inflammatory cytokine, Moxibustion, Ulcerative colitis",
author = "Qin Qi and Liu, {Ya Nan} and Xiaoming Jin and Zhang, {Lin Shuang} and Cun Wang and Bao, {Chun Hui} and Liu, {Hui Rong} and Wu, {Huan Gan} and Wang, {Xiao Mei}",
year = "2018",
month = "7",
day = "28",
doi = "10.3748/wjg.v24.i28.3130",
language = "English (US)",
volume = "24",
pages = "3130--3144",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "28",

}

TY - JOUR

T1 - Moxibustion treatment modulates the gut microbiota and immune function in a dextran sulphate sodium-induced colitis rat model

AU - Qi, Qin

AU - Liu, Ya Nan

AU - Jin, Xiaoming

AU - Zhang, Lin Shuang

AU - Wang, Cun

AU - Bao, Chun Hui

AU - Liu, Hui Rong

AU - Wu, Huan Gan

AU - Wang, Xiao Mei

PY - 2018/7/28

Y1 - 2018/7/28

N2 - AIM To investigate the effect and mechanism of moxibustion in rats with ulcerative colitis. METHODS A rat colitis model was established by administering 4% dextran sulphate sodium solution. Seventy male rats were randomly divided into seven groups: Healthy controls (HC), ulcerative colitis model group (UC), UC with 7 d of moxibustion (UC-7), UC with 14 d of moxibustion (UC-14), UC with mesalazine gavage (UC-W), HC with 7 d of moxibustion (HC-7), HC with 14 d of moxibustion (HC-14). Moxibustion was applied to the bilateral Tianshu (ST25). Gut microbiome profiling was conducted by 16S rRNA amplicon sequencing, and PCR and ELISA determined the expression of inflammatory cytokines in colon mucosa and serum, respectively. RESULTS Moxibustion treatment restored the colonic mucosa and decreased submucosal inflammatory cell infiltration in colitis rats. Rats treated with moxibustion and mesalazine had significantly lower levels of the dominant phyla Proteobacteria and the genera Saccharibacteria , Sphingomonas and Barnesiella than colitis rats, and they could restore the microbiome to levels similar to those observed in healthy rats. UC rats had reduced alpha diversity, which could be alleviated by moxibustion therapy, and UC-7 had a higher alpha diversity than UC-14. This finding suggests that short-term (7 d) but no longer term (14 d) moxibustion treatment may significantly affect the gut microbiome. The potential bacterial functions affected by moxibustion may be ascorbate and aldarate metabolism, and amino acid metabolism. Compared with HC group, the levels of the cytokines interleukin-12 (IL-12) (P < 0.05) and IL-6, IL-17, IL-23, interferon-?, lipopolysaccharide, IgA, tumour necrosis factor-a and its receptors 1 (TNFR1) and TNFR2 (P < 0.01) were all increased, whereas anti-inflammatory cytokine IL-2 and IL-10 (P < 0.01) and transforming growth factor-β (P < 0.05) were decreased in UC rats. These changes were reversed by moxibustion. Our findings suggest that moxibustion exerts its therapeutic effect by repairing mucosal tissue damage and modulating the gut microbiome and intestinal mucosal immunity.

AB - AIM To investigate the effect and mechanism of moxibustion in rats with ulcerative colitis. METHODS A rat colitis model was established by administering 4% dextran sulphate sodium solution. Seventy male rats were randomly divided into seven groups: Healthy controls (HC), ulcerative colitis model group (UC), UC with 7 d of moxibustion (UC-7), UC with 14 d of moxibustion (UC-14), UC with mesalazine gavage (UC-W), HC with 7 d of moxibustion (HC-7), HC with 14 d of moxibustion (HC-14). Moxibustion was applied to the bilateral Tianshu (ST25). Gut microbiome profiling was conducted by 16S rRNA amplicon sequencing, and PCR and ELISA determined the expression of inflammatory cytokines in colon mucosa and serum, respectively. RESULTS Moxibustion treatment restored the colonic mucosa and decreased submucosal inflammatory cell infiltration in colitis rats. Rats treated with moxibustion and mesalazine had significantly lower levels of the dominant phyla Proteobacteria and the genera Saccharibacteria , Sphingomonas and Barnesiella than colitis rats, and they could restore the microbiome to levels similar to those observed in healthy rats. UC rats had reduced alpha diversity, which could be alleviated by moxibustion therapy, and UC-7 had a higher alpha diversity than UC-14. This finding suggests that short-term (7 d) but no longer term (14 d) moxibustion treatment may significantly affect the gut microbiome. The potential bacterial functions affected by moxibustion may be ascorbate and aldarate metabolism, and amino acid metabolism. Compared with HC group, the levels of the cytokines interleukin-12 (IL-12) (P < 0.05) and IL-6, IL-17, IL-23, interferon-?, lipopolysaccharide, IgA, tumour necrosis factor-a and its receptors 1 (TNFR1) and TNFR2 (P < 0.01) were all increased, whereas anti-inflammatory cytokine IL-2 and IL-10 (P < 0.01) and transforming growth factor-β (P < 0.05) were decreased in UC rats. These changes were reversed by moxibustion. Our findings suggest that moxibustion exerts its therapeutic effect by repairing mucosal tissue damage and modulating the gut microbiome and intestinal mucosal immunity.

KW - 16S rRNA

KW - Gut microbiome

KW - Inflammatory cytokine

KW - Moxibustion

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=85051216950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051216950&partnerID=8YFLogxK

U2 - 10.3748/wjg.v24.i28.3130

DO - 10.3748/wjg.v24.i28.3130

M3 - Article

C2 - 30065559

AN - SCOPUS:85051216950

VL - 24

SP - 3130

EP - 3144

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 28

ER -